Onchocerciasis News and Research RSS Feed - Onchocerciasis News and Research

Onchocerciasis is a parasitic disease caused by the filarial worm Onchocerca volvulus. It is transmitted through the bites of infected blackflies of Simulium species, which carry immature larval forms of the parasite from human to human. In the human body, the larvae form nodules in the subcutaneous tissue, where they mature to adult worms. After mating, the female adult worm can release up to 1000 microfilariae a day. These move through the body, and when they die they cause a variety of conditions, including blindness, skin rashes, lesions, intense itching and skin depigmentation. Onchocerciasis is endemic in more than 25 nations located in a broad band across the central part of Africa. Small endemic foci are also present in the Arabian Peninsula (Yemen) and in the Americas (Brazil, Colombia, Ecuador, Guatemala, southern Mexico, and Venezuela).
Researchers sequence genome of parasitic worm that causes river blindness

Researchers sequence genome of parasitic worm that causes river blindness

Scientists have sequenced the genome of the parasitic worm responsible for causing onchocerciasis--an eye and skin infection more commonly known as river blindness. [More]
Controlling corneal blindness by 2030: an interview with Dr Pravin Vaddavalli

Controlling corneal blindness by 2030: an interview with Dr Pravin Vaddavalli

Corneal blindness is estimated to be the second most prevalent cause of blindness in many less developed countries. Globally, bilateral corneal blindness is estimated to afflict 4.9 million persons and accounts for 12% of 39 million blind, utilizing WHO 2010 global blindness data. [More]
PATH and SD/Alere announce commercial availability of two diagnostic tools for NTDs

PATH and SD/Alere announce commercial availability of two diagnostic tools for NTDs

PATH and Standard Diagnostics/Alere announced today the commercial availability of two rapid diagnostic tools for onchocerciasis and lymphatic filariasis. Designed for use in disease surveillance, the antibody-based tests are part of a suite of diagnostic innovations intended to support the elimination of neglected tropical diseases (NTDs), a group of illnesses that affect more than a billion people worldwide. [More]
Researchers take major step towards developing vaccine for river blindness

Researchers take major step towards developing vaccine for river blindness

The world's first vaccine for a disease that causes misery for millions in Africa could be tested within five years. [More]
Kilimanjaro Project receives 2015 António Champalimaud Vision Award

Kilimanjaro Project receives 2015 António Champalimaud Vision Award

The 2015 António Champalimaud Vision Award is given to three institutions that have developed a unique collaborative project to achieve the common goal of fighting blindness and poverty in Africa. [More]
Researchers receive Bill & Melinda Gates Foundation grant to eliminate neglected tropical diseases

Researchers receive Bill & Melinda Gates Foundation grant to eliminate neglected tropical diseases

Researchers at Washington University School of Medicine in St. Louis have received a $7 million grant from the Bill & Melinda Gates Foundation aimed at eliminating river blindness and elephantiasis, two neglected tropical diseases that annually sicken millions. [More]
Smartphone checks blood for parasitic disease

Smartphone checks blood for parasitic disease

New Smartphone technology has been developed that can detect and count wriggling parasitic worms in a drop of blood... [More]
WHO urges affected countries to increase investment in tackling neglected tropical diseases

WHO urges affected countries to increase investment in tackling neglected tropical diseases

WHO urges affected countries to scale up their investment in tackling 17 neglected tropical diseases in order to improve the health and well-being of more than 1.5 billion people. This investment would represent as little as 0.1% of current domestic expenditure on health in affected low and middle income countries for the period 2015-2030. [More]
COUNTDOWN research consortium focuses on neglected tropical diseases

COUNTDOWN research consortium focuses on neglected tropical diseases

The COUNTDOWN research consortium has been launched today following a £7 million grant allocation from the UK Department for International Development earlier in the year. [More]
DNDi awarded USAID grant to develop new treatments for river blindness, elephantiasis

DNDi awarded USAID grant to develop new treatments for river blindness, elephantiasis

The Drugs for Neglected Diseases initiative has been awarded US$ 10 million by the United States Agency for International Development to develop new treatments for onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) - the first-ever USAID grant for neglected tropical disease research and development (R&D). [More]
Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm. [More]
Grand Challenges Canada announces $1.2 million in grant for 11 new global health innovations

Grand Challenges Canada announces $1.2 million in grant for 11 new global health innovations

Grand Challenges Canada, funded by the Government of Canada, today announced $1.2 million in funding for 11 new global health innovations implemented in member states of La Francophonie. [More]
New, easy-to-use test to accelerate progress toward eliminating onchocerciasis in Africa

New, easy-to-use test to accelerate progress toward eliminating onchocerciasis in Africa

A new test will accelerate global progress toward eliminating onchocerciasis, a leading cause of preventable blindness in Africa. PATH, an international nonprofit health organization, today announced the availability of the SD BIOLINE Onchocerciasis IgG4 rapid test, manufactured and distributed by Standard Diagnostics, Inc. [More]
Blackflies infected with Onchocerca volvulus parasite may spread nodding syndrome

Blackflies infected with Onchocerca volvulus parasite may spread nodding syndrome

Despite decades of research, scientists have yet to pinpoint the exact cause of nodding syndrome (NS), a disabling disease affecting African children. A new report suggests that blackflies infected with the parasite Onchocerca volvulus may be capable of passing on a secondary pathogen that is to blame for the spread of the disease. New research is presented in the International Journal of Infectious Diseases. [More]
Celgene Global Health, DNDi expand partnership to identify new drug candidates for NTDs

Celgene Global Health, DNDi expand partnership to identify new drug candidates for NTDs

Celgene Global Health, a division of Celgene Corporation, and the Drugs for Neglected Diseases initiative strengthen their collaboration with a four-year Research Collaboration Agreement to identify and optimize new drug candidates for the treatment of neglected tropical diseases (NTDs). [More]
Researchers developing new medication to tackle river blindness and elephantiasis

Researchers developing new medication to tackle river blindness and elephantiasis

Researchers are developing new drug treatments to tackle river blindness and elephantiasis, which affect up to 150 million people across the world. [More]
GHIT Fund announces grants to speed up innovative drug development for neglected diseases

GHIT Fund announces grants to speed up innovative drug development for neglected diseases

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced three grants worth a total of US$6.8 million to speed the development of innovative drugs for some of the world’s most neglected diseases—schistosomiasis, Chagas disease and parasitic roundworms. [More]
LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis. [More]
Study finds persistent deficiency in new therapeutics for neglected diseases

Study finds persistent deficiency in new therapeutics for neglected diseases

In a study published today in the open-access journal The Lancet Global Health, the Drugs for Neglected Diseases initiative and other researchers report a persistent deficiency in truly new therapeutics for neglected diseases, despite nominal progress and an acceleration in research and development efforts. This continued 'fatal imbalance' in medical R&D points to the urgent need to develop and deliver groundbreaking new treatments for the world's poorest and most neglected patients. [More]
LSTM professor awarded The Manson Medal for outstanding contribution in field of tropical medicine

LSTM professor awarded The Manson Medal for outstanding contribution in field of tropical medicine

The Liverpool School of Tropical Medicine (LSTM) is delighted that Emeritus Professor and Senior Professional Fellow, David Molyneux, has been awarded The Manson Medal, the Royal Society of Tropical Medicine and Hygiene's highest mark of distinction. [More]
Advertisement
Advertisement